roundhill glp-1 & weight loss etf drug bets big on Eli Lilly, Novo Nordisk The obesity drug market is

The Role of Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RA) in Diabetes-Related Neurodegenerative Diseases

A further investigation [14] aimed to estimate whether there is an elevated risk of intestinal obstruction associated with GLP-1RAs and DPP-4 inhibitors compared to sodium-glucose cotransporter-2 (SGLT-2) inhibitors

A new method of classifying prognostic comorbidity in longitudinal studies: development and validation

This rapid adoption through novel care delivery models underscores the urgent need for robust safety surveillance and comparative effectiveness research, including ones specifically focused on semaglutide